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Abstract
AIM: The heptadecapeptide nociceptin alias orphanin FQ is
the endogenous agonist of opioid receptor-like1 receptor.
It is involved in modulation of pain and cognition. High blood
level was reported in patients with acute and chronic pain,
and in Wilson disease. An accidental observation led us to
investigate nociceptin in hepatocellular carcinoma.
METHODS: Plasma nociceptin level was measured by
radioimmunoassay, aprotinin was used as protease inhibitor.
Hepatocellular carcinoma was diagnosed by laboratory,
ultrasound, other imaging, and confirmed by fine needle
biopsy. Results were compared to healthy controls and
patients with other chronic liver diseases.
RESULTS: Although nociceptin levels were elevated in
patients with Wilson disease (14.0±2.7 pg/mL, n=26),
primary biliary cirrhosis (12.1±3.2 pg/mL, n=21) and liver
cirrhosis (12.8±4.0 pg/mL, n=15) compared to the healthy
controls (9.2±1.8 pg/mL, n=29, P<0.001 for each), in patients
with hepatocellular carcinoma a ten-fold increase was found
(105.9±14.4 pg/mL, n=29, P<0.0001). High plasma levels
were found in each hepatocellular carcinoma patient
including those with normal alpha fetoprotein and those with
pain (104.9±14.9 pg/mL, n=12) and without (107.7±14.5
pg/mL, n=6).
CONCLUSION: A very high nociceptin plasma level seems
to be an indicator for hepatocellular carcinoma. Further
research is needed to clarify the mechanism and clinical
significance of this novel finding.
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INTRODUCTION
The heptadecapeptide nociceptin (N/OFQ), alias orphanin FQ,
is the endogenous agonist ligand of a G-protein-coupled,
naloxon insensitive opioid receptor-like 1 receptor (ORL1),
recently named as NOP[1]. Although N/OFQ is structurally
related to opioid peptides, especially to dynorphin A, it does
not interact with m, d and k receptors. The nociceptin/NOP
system represents a new peptide-based signalling pathway.
Nociceptin is involved in a number of pharmacological actions
in the central nervous system (CNS), including modulation of
pain and cognition. However, numerous studies investigating
the functional role of nociceptin in physiology have failed to
provide coherent view, and its exact physiological role remains
to be determined[2,3]. Although N/OFQ is produced by some
brain structure and peripheral neurons, it is present in the liquor
and blood[4], and recent data prove that nociceptin transcripts
are expressed in human immune cells as well[5]. NOP mRNA
is expressed not only in nervous system, but in immune cells
and other organs including the liver[6-8]. High nociceptin blood
level was shown in patients with acute and chronic pains[9],
and Wilson disease[10].
     An accidental observation led us to investigate plasma
nociceptin level in patients with hepatocellular carcinoma
(HCC). While measuring plasma nociceptin in patients with
Wilson disease, we noticed that in one patient the nociceptin
level was extremely high compared both with the controls and
other Wilson patients. This patient had liver cirrhosis and
primary hepatocellular carcinoma without any pain. This
observation prompted us to study N/OFQ in patients with
hepatocellular carcinoma and other liver diseases. Striking
differences were found.
MATERIALS AND METHODS
Patients
Plasma nociceptin level was measured in 26 patients with
Wilson disease (aged from 14-55 years, 11 with hepatic, and
15 with neurological symptoms, each D-penicillamine treated),
21 patients with primary biliary cirrhosis (age ranged from
36-72 years; each woman with AMA M2 positive,
histologically proven and treated with ursodeoxycholic acid;
mean disease duration: 9.4 years), 18 patients with chronic
hepatitis (14 HCV positive, 1 HBV positive and 3 autoimmune,
each proved by liver biopsy), 15 patients with liver cirrhosis
(9 alcoholic, 6 HCV positive), and 18 patients with primary
hepatocellular carcinoma (8 with alcoholic cirrhosis, 6 HCV
cirrhosis, 1 HBV cirrhosis, 1 Wilson disease, 1 PBC, and 1
patient without any underlying liver disease) from the
Hepatological Unit, the 1st Department of Medicine, the
Semmelweis University, Budapest. The diagnosis of HCC was
based on clinical laboratory tests, US, CT, MRI findings and
was confirmed by fine needle aspiration cytology, and
histology, in which 3 cases underwent surgery, and one case
by autopsy. Serum alpha fetoprotein (AFP) was elevated in
11 out of 18 HCC patients. The size of the tumour ranged
from 2.5 cm to 12 cm in diameter. It was smaller than 5 cm in
5 patients, and larger than 5 cm in 13 patients. No metastasis
was found outside the liver. In the HCC group 12 patients had
temporary pain treated with non-opioid analgetics and 6
patients were without any pain.
     Two scoring systems were used for characterisation of
patients with HCC. The distribution of patients according to
the Barcelona Clinic Liver Cancer (BCLC) classification[11],
which includes the performance status, single or multifocal
appearance of the tumor, vascular invasion, portal hypertension,
Okuda stage and Child-Pugh classification: Stage A1 (n=5),
stage A4 (n=6), stage B (n=3) and stage D (n=4). Ranking of
patients according to the Cancer of the Liver Italian Program
group (CLIP) criteria[12,13], which includes Child-Pugh stage,
tumor morphology and extent, presence of portal vein
thrombosis and serum level of alpha fetoprotein: CLIP 0 (n=2),
CLIP 1 (n=5), CLIP 2 (n=5), CLIP 3 (n=4), CLIP 4 (n=1),
CLIP 5 (n=1). Demographics, clinical data and ranking of HCC
patients according to the BCLC and CLIP classification are
shown in Table 1.
      Twenty-nine healthy persons including blood donors and
members of the medical staff served as control group. The study
was approved by the Local Regional Committee of Science
and Research Ethics. Written informed consent was obtained.
Methods
Blood drawn from fasting subjects between 08:00 and 10:00
AM was collected in vacutainer tubes containing K-EDTA as
anticoagulant. Aprotinin was added immediately as protease
inhibitor. Plasma samples were stored at minus 80 . Nociceptin
was measured by radioimmunoassay (125I-Nociceptin kit,
Phoenix Pharmaceuticals, Phoenix, CA, USA) with minimum
sensitivity of 1 pg/mL, as described before[9]. Comparison of
the plasma N/OFQ concentration in groups was made using Mann-
Whitney U Test. Correlation between N/OFQ level and liver
function test results was evaluated by Spearmann RO correlation.
RESULTS
Results are shown in Figure 1. Although nociceptin levels
were elevated in patients with Wilson disease (14.0±2.7 pg/mL),
in patients with PBC (12.1±3.2 pg/mL) and liver cirrhosis
(12.8±4.0 pg/mL) compared to the healthy controls (9.2±1.8
pg/mL,  P<0.001 for each), more than ten-fold higher values
were found (105.9±14.4 pg/mL, P<0.0001) in patients with
HCC. In patients with chronic hepatitis the N/OFQ level was
10.2±3.6, but the difference was not significant compared to
the healthy controls. The clinical data, chemical laboratory
findings, AFP and N/OFQ levels of  patients with HCC are
individually indicated in Table 1.
Figure 1  Plasma nociceptin level (pg/mL±SD) in healthy con-
trols (Control) and in patients with Wilson disease (Wilson),
primary biliary cirrhosis (PBC), chronic hepatitis (CH), cirrho-
sis and hepatocellular carcinoma (HCC). aP<0.001 vs control,
bP<0.0001 vs control and each other group.
      We did not find any correlation between nociceptin level
and liver chemical laboratory tests including AFP in any group
of patients with liver disease. Nociceptin was elevated in each
HCC patient including those with normal AFP. The N/OFQ
level did not show correlation with the presence and severity
of the pain. High levels were found in subgroups of patients
with pain (104.9±14.9 pg/mL, n=12) and without pain
(107.7±14.5 pg/mL, n=6). There was no difference in nociceptin
level between groups with tumor size smaller than 5 cm and
larger than 5 cm (109.4±16.5, n=5 and 115.2±12.7, n=13,
Table 1  Profile of patients with HCC and plasma N/OFQ levels
       Age   Gender    Aetiology       AFP       Tumor size            Uni-     Multi-     BCLC   CLIP        Bi           ALP      GGT    Ascites   C-P     N/OFQ
          y               (ng/mL)        in UH            nod.      nod.        st.cl.       cl.     (mg/dL)  (U/L)   (U/L)              (pg/mL)
  1    80          M       Alcoholic    937     15×11 cm + A 4  3 1.72    306    102       -     A 108.39
  2    64          M       Alcoholic 1 385.9     5×7×6 cm + A 1  1 1.92    242    107       -     A   95.02
  3    60          M       Alcoholic      89     5 -15 mm and 3 cm + B  2 1.07 2 169 1 000       -     B   96.05
  4    62          M       Alcoholic      91     1-1.5 cm and 3.5 cm + B  2 1.12 2 038    995       -     B 104.17
  5    80          M       Alcoholic    937     15×11 cm + A 1  3 1.71    306    102       -     A 111.59
  6    70          M       Alcoholic    459     7×6 cm + A 1  2 0.78    192      68       -     A 111.51
  7    59          M       Alcoholic        7.7     23 mm + D  2 8.32      44.3      97       -     C 128
  8    66          M       Alcoholic        2     1.5 cm + A 1  0 1.25    192      24       -     A   81.6
  9    48          F       HCV      15     6×6 cm + A 4  1 5.75 1 766    253       -     B   90.41
10    66          M       HCV    171     two, 2×2 cm lesion + A 4  1 2.55    460    232       -     A   89.81
11    76          M       HCV        9     6×7 cm + 5×4 cm + D  4         13.91    834    276       +     C 114.65
12    78          M       HCV    350     5×6 cm + A 1  0 0.68    270      37       -     A 114.7
13    48          F       HCV      13     21×20 mm + B  1 1.36    474 1 060       -     A 128
    and 16×21 mm
14    81          M       HCV 1 050     8×10 cm + A 4  3 3    569    517       -     A   98.31
15    66          M       HBV         6     4×4.5 cm + D  2 3.35    442    199       +     C 106.03
16    45          F       WD         5     60×46 mm + A 4  1 0.42    910    212       +     B 128
17    68          F       PBC 3 480     11×7.5 cm + D  5 4.79 1 856    960       +     C 172.2
18    32          F       Unknown 1 050     100×85×180 mm +  A 4  3 0.34    233      24       -     -   85.5
AFP=alpha fetoprotein, BCLC st. cl.=Barcelona Clinic Liver Cancer (BCLC) staging classification, CLIP cl.=Cancer of the Liver
Italian Program Group (CLIP) scoring system, Bi=Serum total bilirubin, ALP=alkaline phosphatase, GGT=gamma glutamyl
transferase, C-P=Child-Pugh score, N/OFQ=nociceptin/orphanin FQ.
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respectively) or between single nodular and multinodular HCC
groups, and even symptomatic or asymptomatic tumors. No
difference was found in the N/OFQ level between any subgroup
of patients with different BCLC and CLIP score values.
     Repeated nociceptin measurements were done in one
patient before and after non-surgical ablation treatment of
HCC. The high nociceptin level did not decrease significantly
at least within 10 days following ethanol injection treatment
of the tumor, since values were 116 pg/mL before, and 110, 108,
112, 103 pg/mL after treatment at 1, 3, 7, and 10 days, respectively.
     However, progressive and significant elevation in plasma
nociceptin level parallel with the increase of AFP was observed
in a PBC patient with HCC during the follow up. This 67 year
old patient was monitored and treated with ursodeoxycholic
acid throughout 18 years when her liver tumor was detected
by yearly regular ultrasound check up. Fine needle aspiration
cytology proved HCC, and she died within two years.
Nociceptin was measured in blood samples collected from
other reason. The AFP level was normal throughout the years,
but elevated at the time of the diagnosis of HCC (426 ng/mL)
and rose up to 3 480 ng/ml. The plasma nociceptin (10.6 pg/mL)
was within the normal range (9.2±1.8 pg/mL) in the tumor
free stage, ten-fold higher (103.7 pg/mL) when the tumor was
diagnosed and reached 172.2 pg/mL before the death. Sixteen-
fold higher nociceptin content was measured in the tumor tissue
(0.16 pg/mg) compared to the tumor-free liver tissue sample
(0.01 pg/mg) taken during the autopsy. Detailed presentation
of this case is published in this issue of World Journal of
Gastroenterology  (Horvath et al World J Gastroenterol 2004;
10: 152-154)
DISCUSSION
Shortly after cloning of the three known opioid receptors a
fourth member of the subfamily of G protein-coupled receptors
was identified. In a search for additional opioid receptor
subtypes, a sequence of an opioid-like receptor, termed ORL1
was found, which, however, did not bind any of the known
natural opioid ligands. Therefore ORL1 represented an “orphan”
receptor. Later two working groups simultaneously reported the
isolation of the natural ligand for ORL1, a 17 aminoacid
polypeptide and named it orphanin FQ or nociceptin[14,15].
      Anatomic studies have revealed high levels of expression
of N/OFQ messenger RNS in brain structures involved in
sensory, emotional and cognitive processing. Like all other
neuropeptides, the heptadecapeptid N/OFQ is synthesized as
a part of a larger precursor named prepro-nociceptin, a 176
aminoacid polypeptide in human, from which N/OFQ and
nocistatin are cleaved in brain cells and peripheral neurons[16,17].
Although nociceptin is present in the brain, the liquor and
blood,  human immune cells and polymorphonuclear cells, the
gastrointestinal tract and other organs, there are no data on
N/OFQ or its receptor in malignant diseases with exception of
human neuroblastoma cell lines[18,19]. This is the first report
focusing on nociceptin in hepatocellular carcinoma and other
liver diseases.
      The novel finding of this study is the striking elevation in
plasma N/OFQ level in patients with hepatocellular carcinoma.
Although nociceptin was elevated in patients with Wilson
disease, primary biliary cirrhosis and liver cirrhosis, very high
levels over ten-fold increase compared with healthy controls
was found in HCC. Since nociceptin level was extremely high
in each patient with HCC, and the difference among HCC
patients and groups of patients with other liver diseases was
highly significant (P<0.0001), the very high plasma level of
nociceptin seems to be an indicator for HCC. It is remarkable
that nociceptin level was very high in even those patients with
normal level of alpha-fetoprotein[20]. The size of HCC is an
important element of prognostic assessment[21]. However,
nociceptin level was equally very high in patients with tumor
size smaller and larger than 5 cm in diameter.
     Further research is needed to clarify the mechanism and
clinical significance of the highly elevated nociceptin level in
HCC. Increased production or decreased catabolism of
nociceptin may be the cause of elevation in plasma level. It is
to be determined whether the tumor produces nociceptin or it
gives signal for brain cells or peripheral neurons to increase
the secretion of N/OFQ. We had the opportunity to determine
the tissue nociceptin content in one PBC patient with HCC.
Although more than 15-fold higher nociceptin content was
measured in the carcinoma tissue than in the tumor-free liver
tissue samples taken during autopsy, it did not necessarily mean
that nociceptin was produced by the tumor. It is also possible
that the tumor simply accumulates nociceptin via binding it
by NOP receptors. This possibility could be supported by the
fact that ORL1/NOP receptor mRNA has been detected in the
liver[22], although no study is yet available on nociceptin or its
receptor mRNA expression in hepatocellular carcinoma tissue.
     Nociceptin is involved in the processing of pain signals,
and it modulates the pain perception[23,24]. However, we did
not find difference in N/OFQ level between patients with pain
and without. There was no correlation between the plasma N/
OFQ level and the severity of pain.
     Whether a very high plasma N/OFQ level is a specific
marker of HCC should be investigated and subjected to further
study. Since nociceptin transcripts are expressed in immune
cells[5], it has also been shown that polymorphonuclear cells
express nociceptin receptors and N/OFQ stimulates neutrophil
chemotaxis and recruitment[25]. The high nociceptin level could
also be an indicator of altered reaction of the body including
immunological, cytokine and other mechanisms. The bacterial
endotoxin (LPS) and proinflammatory cytokines including
TNF-alpha, commonly increased in malignancies, induce N/OFQ
mRNS in astrocytes. It may suggest a role for nociceptin in
neural-glial communication and in inflammatory responses[26].
     In humans, the N/OFQ gene has been mapped to the
chromosomal location 8p21[27]. Transcription of this gene was
shown to be enhanced by cytokines, neurotrophic factors[26],
also by estrogen[28]. This cAMP-dependent transcription could
be blocked by glucocorticoids[19]. Our patients in this study
have not received glucocorticoid treatment, and only one PBC
patient used transdermal estrogen hormone replacement for
osteoporosis prevention.
    Elevated N/OFQ level might partly represent a
compensatory mechanism in the nociceptin/NOP system to
modulate pain perception in the central nervous system. That
mechanism might explain why some patients with a very high
plasma N/OFQ level did not have any pain despite advanced
stage of the malignant liver tumor. It is remarkable that
nociceptin in HCC patients was 3-fold higher than the
highest values reported in patients with chronic pain without
malignant diseases[9]. We believe that our results could
stimulate further investigation.
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